Molecular and Clinical characteristics of ROS1 Fusion Variants in ROS1-rearranged Cancers: A Defined Role of Fusion Partners and Breakpoints of ROS1
Canonical fusion partners with introns 33 and 34 of ROS1 may be the most optimal predictors for ROS1-TKI benefit. Precise characterization of the variants in terms of ROS1 breakpoints could be important for patient stratification in ROS1-rearranged cancers.
Authors
- Josephina Sampson (ORCID: https://orcid.org/0000-0002-0147-6014)
- Shinkyo Yoon (ORCID: https://orcid.org/0000-0001-7544-0404)
- Jene Choi (ORCID: https://orcid.org/0000-0001-7618-7519)
- Richard Bayliss (ORCID: https://orcid.org/0000-0003-0604-2773)
- Yeokyeong Shin (ORCID: https://orcid.org/0009-0000-0403-2091)
- Deokhoon Kim (ORCID: https://orcid.org/0000-0002-3597-1048)
- Ji‐Seon Jeong (ORCID: https://orcid.org/0000-0002-9750-981X)
Institutions
- Ulsan College (KR)
- University of Leeds (GB)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Institute of Structural and Molecular Biology (GB)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1016/j.ejca.2025.116091
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00